Cargando…
Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, et al. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Adv. 2022;6(3):828-847.
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
The American Society of Hematology
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958207/ https://www.ncbi.nlm.nih.gov/pubmed/36716115 http://dx.doi.org/10.1182/bloodadvances.2022007404 |
| _version_ | 1784894976910426112 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9958207 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | The American Society of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-99582072023-02-26 Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, et al. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Adv. 2022;6(3):828-847. Blood Adv Erratum The American Society of Hematology 2023-02-14 /pmc/articles/PMC9958207/ /pubmed/36716115 http://dx.doi.org/10.1182/bloodadvances.2022007404 Text en © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Erratum Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, et al. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Adv. 2022;6(3):828-847. |
| title | Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, et al. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Adv. 2022;6(3):828-847. |
| title_full | Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, et al. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Adv. 2022;6(3):828-847. |
| title_fullStr | Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, et al. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Adv. 2022;6(3):828-847. |
| title_full_unstemmed | Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, et al. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Adv. 2022;6(3):828-847. |
| title_short | Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, et al. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Adv. 2022;6(3):828-847. |
| title_sort | menghrajani k, gomez-arteaga a, madero-marroquin r, et al. risk classification at diagnosis predicts post-hct outcomes in intermediate-, adverse-risk, and kmt2a-rearranged aml. blood adv. 2022;6(3):828-847. |
| topic | Erratum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958207/ https://www.ncbi.nlm.nih.gov/pubmed/36716115 http://dx.doi.org/10.1182/bloodadvances.2022007404 |